The Europe hospital acquired disease testing market is currently witnessing robust growth. Hospital-acquired diseases (HAD), or nosocomial infections, are illnesses caused by exposure to viral, bacterial and fungal pathogens during hospital visits. Some commonly known infections are catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The various tests used to diagnose these infections are complete blood count (CBC) test, erythrocyte sedimentation rate (ESR) test, and urinalysis, cultures of the infected area, blood, urine and other body fluids. Other diagnostic tests, such as antimicrobial susceptibility testing (AST), are conducted for the testing of tuberculosis.
The increasing prevalence of hospital-acquired infections across Europe is one of the key factors driving the market. Furthermore, various technological advancements, such as the development of innovative diagnostic instruments and technologies, including flow cytometry, mass spectrometry and near-infrared spectroscopy, are providing a boost to the market growth. Additionally, the growing awareness regarding HADs and the available treatment options among patients, along with extensive research and development (R&D) in the field of medical sciences, are contributing to the growth of the market. Looking forward, IMARC Group expects the market to continue its robust growth during 2021-2026.
IMARC Group provides an analysis of the key trends in each sub-segment of the Europe hospital acquired disease testing market report, along with forecasts for growth at the region level from 2021-2026. Our report has categorized the market based on region and indication.
Breakup by Indication:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at